---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-018181"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2024-04-05T23:59:59+00:00"
generated_at: "2026-06-04T01:44:16.674967+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bionano Genomics raises $10M via registered direct offering of common stock and warrants at $1.145/share

## Summary
- Issues 8.73M shares (or equivalents) and warrants to purchase 8.73M shares at $1.02; exercise price $1.02, 5-year term.
- Gross proceeds ~$10M; net proceeds for working capital, R&D, debt repayment, and capex.
- Expected closing on April 8, 2024; H.C. Wainwright acts as sole placement agent with 6% cash fee.
- Offered under effective shelf registration statement (File No. 333-270459); warrants include beneficial ownership limitations of 4.99%/9.99%.

## SEC filing metadata
- accession: 0001140361-24-018181
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2024-04-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000114036124018181/0001140361-24-018181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000114036124018181/ef20026117_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-018181
- JSON: https://secwatch.observer/filing/0001140361-24-018181.json
- Plain text: https://secwatch.observer/filing/0001140361-24-018181.txt

## Key facts
- Material Agreements
  Bionano Genomics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $10.0 million (effective 2024-04-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: approximately $10.0 million
  - Effective: 2024-04-04
  source text: On April 4, 2024, Bionano Genomics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market consistent with the rules of the Nasdaq Stock Market (the “Registered Direct Offering”): (i) an aggregate of 6,536,682 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), (ii) pre-funded warrants to purchase up to an aggregate of 2,196,944 shares of Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase up to 8,733,626 shares of Common Stock (the “Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000114036124018181/0001140361-24-018181-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.